Livzon Pharmaceutical Launches Tender Offer For Vietnam's Imexpharm, Raising Bid to 1.85 Billion Yuan

MT Newswires Live

Dec 31, 2025

Livzon Pharmaceutical Group (HKG:1513, SHE:000513) has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm (HOSE:IMP), raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.

The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.

Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry (SHA:600380) said in a Shanghai Stock Exchange filing on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2595574913"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2595574913\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2595574913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 09:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595574913","market":"sh","top_or_hot":-1,"title":"Livzon Pharmaceutical Launches Tender Offer For Vietnam's Imexpharm, Raising Bid to 1.85 Billion Yuan","media":"MT Newswires Live","content":"<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm (HOSE:IMP), raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.</p><p>The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.</p><p>Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry (SHA:600380) said in a Shanghai Stock Exchange filing on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharmaceutical Launches Tender Offer For Vietnam's Imexpharm, Raising Bid to 1.85 Billion Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharmaceutical Launches Tender Offer For Vietnam's Imexpharm, Raising Bid to 1.85 Billion Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-31 09:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm (HOSE:IMP), raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.</p><p>The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.</p><p>Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry (SHA:600380) said in a Shanghai Stock Exchange filing on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0114","symbol_name":"健康中国","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2595574913","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595574913","pubTimestamp":1767143284,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Livzon Pharmaceutical Group  has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm , raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry  said in a Shanghai Stock Exchange filing on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600380":"健康元","BK0114":"健康中国","BK0077":"质押式回购","01513":"丽珠医药","BK0046":"生物疫苗","BK1191":"制药","BK0187":"一线龙头","BK0028":"国家队","000513":"丽珠集团","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"丽珠医药对越南Imexpharm发起要约收购出价上调至18.5亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600380":0.9,"01513":0.9,"000513":0.9},"content_text":"Livzon Pharmaceutical Group (HKG:1513, SHE:000513) has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm (HOSE:IMP), raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry (SHA:600380) said in a Shanghai Stock Exchange filing on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}